Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study

European Urology

Volumn 52, Issue 4, 2007, Pages 1020-1027

  Di Lorenzo, Giuseppe ^a   Autorino, Riccardo ^b   Perdonà, Sisto ^c   De Laurentiis, Michele ^a   D'Armiento, Massimo ^b   Cancello, Giuseppe ^a   Mirone, Vincenzo ^a   Imbimbo, Ciro ^a   Longo, Nicola ^a   Altieri, Vincenzo ^a   Tortora, Gianpaolo ^a   Figg, William D ^d   De Placido, Sabino ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Hormone refractory prostate cancer; Prostate specific antigen; Toxicity

Indexed keywords

DOCETAXEL; NAVELBINE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; ALOPECIA; ANALGESIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOCARCINOMA; AGED; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; SURVIVORS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 34548231830     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.02.060     Document Type: Article

References (34)

1. Jamal A., Murray T., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 10-30
2. Pienta K., and Smith D. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55 (2005) 300-318
3. Yagoda A., and Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71 (1993) 1098-1109
4. Tannock I.F., de Wit R., Berry W., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
5. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
6. Fields-Jones S., Koletsky A., Wilding G., et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone refractory prostate cancer: a phase II trial. Ann Oncol 10 (1999) 1307-1310
7. Sweeney C.J., Monaco F.J., Jung S.H., et al. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone refractory prostate cancer. Ann Oncol 13 (2002) 435-440
8. Oudard S., Caty A., Humblet Y., et al. Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol 12 (2001) 847-852
9. Kreis W., Budman D.R., and Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 79 (1997) 196-202
10. Hainsworth J.D., Burris III H.A., Billings III F.T., et al. Weekly docetaxel with either gemcitabine or vinorelbine as second line treatment in patients with advanced non small cell lung carcinoma. Cancer 92 (2001) 2391-2398
11. Di Lorenzo G., Pizza C., Autorino R., et al. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. Eur Urol 46 (2004) 712-716
12. Miller V.A., Krug L.M., Ng K.K., et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non small cell lung cancer. J Clin Oncol 18 (2000) 1346-1350
13. Gravis G., Bladou F., Salem N., et al. Weekly administration of docetaxel for symptomatic metastatic hormone refractory prostate carcinoma. Cancer 15 (2003) 1627-1634
14. Lee M.V., Fong E.M., Singer F.R., et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61 (2001) 2602-2608
15. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882
16. National Cancer Institute. Common Termination Criteria for Adverse Events, version 3.0. 2003.
17. Cleeland C.S., and Ryan K.M. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23 (1994) 129-138
18. Tong D., Gillick L., and Hendrickson F.R. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer 50 (1982) 893-899
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-13
20. Kaplan Z.L., and Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
21. Hinsworth J.D., Burris III H.A., Erland J.B., et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 22 (2004) 2532-2539
22. Budman D.R., Calabro A., Kreiss W., et al. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 13 (2002) 1011-1016
23. Morant R., Hsu Schmitz S.F., Bernard J., et al. Vinorelbine in androgen-dependent metastatic prostatic carcinoma: a phase II study. Eur J Cancer 38 (2002) 1626-1632
24. Brubaker K.D., Brown L.G., Vessella R.L., and Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environmentm. BMC Cancer 6 (2006) 15-21
25. Ullen A., Lennartsson L., Harmenberg U., et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 6 (2005) 644-650
26. Bertelli G., Heouaine A., Arena G., et al. Weekly docetaxel and zoledronic acid every 4 weeks in hormone refractory prostate cancer patients. Cancer Chemother Pharmacol 57 (2006) 46-51
27. Vordos D., Paule B., Vacherot F., et al. Docetaxel and zoledronic acid in patients with metastatic hormone refractory prostate cancer. BJU Int 94 (2004) 524-527
28. Goodin S., Rao K.V., Kane M., et al. A phase II trial of docetaxel and vinorelbine in patients with hormone refractory prostate cancer. Cancer Chemother Pharmacol 56 (2005) 199-204
29. Koletsky A.J., Guerra M.L., Kronish L., et al. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone refractory prostate cancer. Cancer J 9 (2003) 286-292
30. Hahn N.M., Marsh S., Fisher W., et al. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine and estramustine in combination in hormone refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 12 (2006) 6094-6099
31. Falsaperla M., Morgia G., Tartarone A., Ardito R., and Romano G. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Eur Urol 47 (2005) 449-455
32. Cabrespine A., Guy L., Gachon F., et al. Circulating chromogranin A and hormone refractory prostate cancer chemotherapy. J Urol 175 (2006) 1347-1352
33. Clarke N.W. Management of the spectrum of the hormone refractory prostate cancer. Eur Urol 50 (2006) 428-438
34. Calabrò F., and Sternberg C.N. Current indications for chemotherapy in prostate cancer patients. Eur Urol 51 (2007) 17-26